Tenaya's Novel Drug TN-301 Shows Superiority in DMD Preclinical Tests

ORLANDO, FL – March 09, 2026 – New preclinical data presented today has ignited fresh hope for patients with Duchenne muscular dystrophy (DMD), a severe and progressive muscle-wasting disease. At the Muscular Dystrophy Association’s 2026 conference, Tenaya Therapeutics unveiled compelling results for its investigational drug, TN-301, demonstrating its potential to not only improve skeletal muscle function but also correct the underlying drivers of the deadly heart complications common in DMD.

In head-to-head studies using preclinical models, Tenaya’s highly selective drug outperformed an already approved therapy, suggesting a potential new chapter in the fight against the devastating genetic disorder. The findings position TN-301 as a promising candidate for near-term clinical trials, addressing a critical unmet need for safer and more effective treatments.

A Disease of Muscle and Heart

Duchenne muscular dystrophy is a relentless genetic disorder, primarily affecting boys, with an incidence of about 1 in every 5,000 male births. Caused by a faulty gene that prevents the body from producing dystrophin—a protein essential for muscle cell integrity—DMD leads to progressive muscle degeneration. Children often show symptoms before age two, face loss of independent mobility by their early teens, and ultimately succumb to the disease as it attacks the muscles of the heart and lungs.

While advances in care have extended lifespans, the core challenges remain. Corticosteroids, a long-standing treatment, come with a heavy burden of side effects. Newer mutation-specific drugs like exon-skippers only help a fraction of patients. The most significant challenge, however, is cardiomyopathy. This weakening of the heart muscle is the leading cause of death for individuals with DMD, and effective treatments that can simultaneously address both skeletal muscle decline and cardiac failure are desperately needed.

It is into this landscape that Tenaya Therapeutics aims to introduce TN-301. The company's research was driven by the recognition that the drug's mechanism could directly counter the cellular dysfunctions that fuel both aspects of DMD.

The Power of Precision: Selective HDAC6 Inhibition

The key to TN-301's potential lies in its precision. The drug is a highly selective inhibitor of histone deacetylase 6 (HDAC6), an enzyme involved in various cellular processes. This stands in stark contrast to givinostat (marketed as Duvyzat), a pan-HDAC inhibitor approved in 2024 that acts on a broad range of HDAC enzymes. While givinostat was a step forward, offering a non-steroidal option for all DMD patients regardless of mutation, its use is limited by side effects like diarrhea, low platelet counts (thrombocytopenia), and a risk of serious heart rhythm changes known as QT prolongation.

Tenaya's preclinical data, presented by Senior Vice President of Research Kathy Ivey, Ph.D., suggest that TN-301's targeted approach may offer the benefits without the same liabilities. Key findings from studies in mdx mice, a standard DMD model, showed that TN-301 treatment improved grip strength to levels seen in healthy mice within five weeks. In contrast, mice treated with givinostat did not achieve the same level of functional recovery.

“DMD-related cardiomyopathy is the most common cause of death among individuals with DMD, and despite advances in care, there is a profound unmet need for treatments that can address both skeletal muscle atrophy and cardiac decline,” said Dr. Ivey. “We conducted a series of studies and found that TN-301 outperformed the approved agent, givinostat, achieving functional improvements in mdx mice that restored muscle performance to wild-type levels while also correcting key DMD-associated cardiomyocyte defects.”

Perhaps the most striking data came from studies on human cardiomyocytes derived from DMD patient stem cells. In these "heart cells in a dish," TN-301 corrected abnormalities in calcium handling and mitochondrial function—two established drivers of DMD cardiomyopathy. Givinostat, the pan-HDAC inhibitor, was reported to actually worsen these critical cardiac defects, highlighting a profound difference between the two drugs' effects on the heart. These results bolster the hypothesis that the benefits seen with pan-HDAC inhibitors may be driven primarily by HDAC6 inhibition, while the off-target effects cause unwanted side effects.

A Crowded Field with Room for Improvement

TN-301 is entering a dynamic but challenging therapeutic landscape. The market includes Sarepta Therapeutics' exon-skipping drugs and its recently approved gene therapy, Elevidys. While groundbreaking, gene therapies face their own hurdles, including potential immune responses and questions about long-term durability. Exon-skipping drugs are only applicable to specific genetic mutations, leaving many patients without a targeted option.

TN-301's potential to be used by all DMD patients, combined with its oral administration and promising safety profile from a Phase 1 study in healthy volunteers, could give it a significant advantage. The Phase 1 trial showed TN-301 was well tolerated and did not demonstrate the dose-limiting toxicities or serious adverse events associated with less selective inhibitors. If these findings are replicated in patient trials, TN-301 could emerge as a superior alternative to givinostat and a valuable component of combination therapy regimens.

A "Pipeline in a Product"

For Tenaya Therapeutics, a clinical-stage biotech focused on heart disease, the positive DMD data adds a significant pillar to its strategy. The company is already developing gene therapies for rare genetic cardiomyopathies, but TN-301 represents a different kind of asset: a small molecule with broad potential.

Beyond DMD, Tenaya has identified heart failure with preserved ejection fraction (HFpEF) as another highly promising indication for TN-301. HFpEF is a vastly prevalent form of heart failure with few effective treatments, representing an enormous market. The drug's multi-modal mechanism—reducing inflammation, oxidative stress, and fibrosis—is highly relevant to the pathophysiology of HFpEF and other cardiac, metabolic, and pulmonary conditions.

This potential for a single drug to treat multiple diseases makes TN-301 a "pipeline in a product," a strategically valuable asset that could attract significant investment and partnership interest. With plans to advance TN-301 toward Phase 2 clinical development for both DMD and HFpEF, Tenaya is poised to test whether the remarkable promise shown in the lab and in early studies can translate into a transformative new medicine for patients in desperate need.